Approval · Notice of Compliance 25158 · 2021
REACTINE ALLERGY: Notice of Compliance 25158
Issued February 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25158
- Date
- February 4, 2021
- Company
- McNeil Consumer Healthcare, division of Johnson & Johnson Inc.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of claim from the product monograph onto the labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE ALLERGY | Not yet assigned | — |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per 5ML